A series of CaMoO₄ phosphors doped with trivalent dysprosium (Dy³⁺) and codoped with potassium (K⁺) ions were prepared by hydrothermal method. The nanostructures of the as-synthesized phosphors were investigated by X-ray diffraction (XRD). The results reveal that the obtained powder phosphors are single-phase scheelite structure with tetragonal symmetry and the crystallite size is in the range of 10–60 nm. The emission spectra show a bright yellow emission at 576 nm and blue emission at 487 nm. As a charge compensator, K⁺ ions were incorporated into CaMoO₄:Dy³⁺ phosphors, which enhance the PL intensities depending on the doping concentration of K⁺. The CIE parameters such as colour coordinates, colour correlated temperature and luminous efficacy of radiation were calculated using spectral energy distribution functions and McCamy's empirical formula. Photometric characterization indicates the suitability of K⁺ compensated CaMoO₄:Dy³⁺ phosphor for white LED applications.

This paper reports on the structural, optical and photometric characterization of an Eu³⁺/Dy³⁺ doped yttrium oxysulfide phosphor (Y₂O₂S:Eu³⁺/Dy³⁺) for near white emission in solid state lighting.

Stereotactic body radiotherapy (SBRT) is an emerging treatment option for liver metastases in patients unsuitable for surgery. We investigated factors associated with clinical outcomes for liver metastases treated with SBRT from a multi-center, international patient registry. Patients with liver metastases treated with SBRT were identified in the RSSearch® Patient Registry. Patient, tumor and treatment characteristics associated with treatment outcomes were assessed. Dose fractionations were normalized to BED10. Overall survival (OS) and local control (LC) were evaluated using Kaplan Meier analysis and log-rank test. The study included 427 patients with 568 liver metastases from 25 academic and community-based centers. Median age was 67 years (31–91 years). Colorectal adenocarcinoma (CRC) was the most common primary cancer. 73% of patients received prior chemotherapy. Median tumor volume was 40 cm3 (1.6–877 cm3), median SBRT dose was 45 Gy (12–60 Gy) delivered in a median of 3 fractions [1–5]. At a median follow-up of 14 months (1–91 months) the median overall survival (OS) was 22 months. Median OS was greater for patients with CRC (27 mo), breast (21 mo) and gynecological (25 mo) metastases compared to lung (10 mo), other gastro-intestinal (GI) (18 mo) and pancreatic (6 mo) primaries (p < 0.0001). Smaller tumor volumes (< 40 cm3) correlated with improved OS (25 months vs 15 months p = 0.0014). BED10 ≥ 100 Gy was also associated with improved OS (27 months vs 15 months p < 0.0001). Local control (LC) was evaluable in 430 liver metastases from 324 patients. Two-year LC rates was better for BED10 ≥ 100 Gy (77.2% vs 59.6%) and the median LC was better for tumors < 40 cm3 (52 vs 39 months). There was no difference in LC based on histology of the primary tumor. In a large, multi-institutional series of patients with liver metastasis treated with SBRT, reasonable LC and OS was observed. OS and LC depended on dose and tumor volume, while OS varied by primary tumor. Future prospective trials on the role of SBRT for liver metastasis from different primaries in the setting of multidisciplinary management including systemic therapy, is warranted. Clinicaltrials.gov: NCT01885299 .

A series of Dy³⁺/K⁺ doped calcium molybdate phosphors were synthesized by a hydrothermal synthesis method and structural, photoluminescence and decay studies were carried out.

This review presents a brief scenario regarding the development of cathodes, anodes, and electrolytes for next-generation Li-ion batteries (LIBs) and supercapacitors for future energy technologies.